EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares it with patients enrolled in prior HFpEF trials.

Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial

Taddei, Stefano
Writing – Review & Editing
;
2020-01-01

Abstract

EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares it with patients enrolled in prior HFpEF trials.
2020
Anker, Stefan D; Butler, Javed; Filippatos, Gerasimos; Khan, Muhammad Shahzeb; Ferreira, João Pedro; Bocchi, Edimar; Böhm, Michael; Rocca, Hans Pieter Brunner-La; Choi, Dong-Ju; Chopra, Vijay; Chuquiure, Eduardo; Giannetti, Nadia; Gomez-Mesa, Juan Esteban; Janssens, Stefan; Januzzi, James L; Gonzalez-Juanatey, Jose R; Merkely, Bela; Nicholls, Stephen J; Perrone, Sergio V; Piña, Ileana L; Ponikowski, Piotr; Senni, Michele; Seronde, Marie-France; Sim, David; Spinar, Jindrich; Squire, Iain; Taddei, Stefano; Tsutsui, Hiroyuki; Verma, Subodh; Vinereanu, Dragos; Zhang, Jian; Jamal, Waheed; Schnaidt, Sven; Schnee, Janet M; Brueckmann, Martina; Pocock, Stuart J; Zannad, Faiez; Packer, Milton
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/1072896
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 22
  • Scopus 89
  • ???jsp.display-item.citation.isi??? 79
social impact